Publication:
Personalizing Treatment Effect Based on Patient's Baseline Profile: A Statistical Modelling Approach Applied to Randomized Clinical Trial and Observational Study Data

Simple item page
dc.contributor.authorBovis, F.
dc.contributor.authorKalincik, T.
dc.contributor.authorLublin, F.
dc.contributor.authorCutter, G.
dc.contributor.authorMalpas, C.
dc.contributor.authorHorakova, D.
dc.contributor.authorHupperts, R.
dc.contributor.authorIDTurkoglu, Recai/0000-0001-9724-851X
dc.contributor.authorIDAltintas, Ayse/0000-0002-8524-5087
dc.contributor.authorIDMcCombe, Pamela/0000-0003-2704-8517
dc.contributor.authorIDFerraro, Diana/0000-0003-4818-3806
dc.date.accessioned2020-06-21T12:26:01Z
dc.date.available2020-06-21T12:26:01Z
dc.date.issued2019
dc.departmentOMÜen_US
dc.department-temp[Bovis, F. -- Sormani, M. P.] Univ Genoa, Dept Hlth Sci, Unit Biostat, Genoa, Italy -- [Kalincik, T. -- Malpas, C.] Univ Melbourne, Dept Med, CORe, Melbourne, Vic, Australia -- [Lublin, F.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA -- [Cutter, G.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA -- [Horakova, D.en_US
dc.description35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS -- SEP 11-13, 2019 -- Stockholm, SWEDENen_US
dc.description.abstract…en_US
dc.description.sponsorshipEuropean Comm Treatment & Res Multiple Sclerosis, Congrex Switzerland Ltden_US
dc.description.sponsorshipTEVA Neuroscience; CIHRCanadian Institutes of Health Research (CIHR); FISM (Fondazione Italiana Sclerosi Multipla)Fondazione Italiana Sclerosi Multipla (FISM); EMD; BiogenBiogen; NovartisNovartis; GenzymeGenzyme Corporationen_US
dc.description.sponsorshipPierre Duquette served on editorial boards and has been supported to attend meetings by EMD, Biogen, Novartis, Genzyme, and TEVA Neuroscience. He holds grants from the CIHR and the MS Society of Canada and has received funding for investigator-initiated trials from Biogen, Novartis, and Genzyme.; JS Wolinsky has served on advisory boards and data monitoring or steering committees, has consulting agreements, and has received speaker honoraria from the following: AbbVie, AcademicCME, ACTRIMS, Alkermes, Bayer HealthCare, Biogen, Bionest, Celgene, Clene Nanomedicine, CMSC, ECTRIMS, EMD Serono, Forward Pharma A/S, MA's Communications, Masters MS, MedDay Pharmaceuticals, Novartis Pharmaceuticals, Otsuka, PRIME, PTC Therapeutics, Roche Genentech, Sanofi Genzyme, Strategic Consultants International, Takeda, Teva Pharmaceuticals, and WebMD; royalties have been received for outlicensed monoclonal antibodies through UTHealth from Millipore Corporation. Claudio Solaro served as advisory board the following companies: Biogen Idec, Merck Serono, Almirall and GW Pharma. He received speaking honoraria from Biogen Idec, Merck Serono. He received research grants and support by the FISM (Fondazione Italiana Sclerosi Multipla).en_US
dc.identifier.endpage790en_US
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.startpage788en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12712/10632
dc.identifier.volume25en_US
dc.identifier.wosWOS:000485303103218
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.journalMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titlePersonalizing Treatment Effect Based on Patient's Baseline Profile: A Statistical Modelling Approach Applied to Randomized Clinical Trial and Observational Study Dataen_US
dc.typeConference Objecten_US
dspace.entity.typePublication

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu